Following the approval of bevacizumab for the treatment of metastatic colorectal cancer, Pune-based Enzene Biosciences has now launched ranibizumab, a biosimilar of the originator medication Lucentis, which is sold in India under the brand name...
DTx can be utilized independently or along with conventional treatments such as medication, face-to-face therapy, as well as various hardware, sensory, or mechanical devices.
Simcere Pharmaceutical Group Limited (Simcere) and Connect Biopharma HongKong Limited (Connect) have entered into an exclusive licensing and partnership agreement for Rademikibart, a novel IL-4Ra monoclonal antibody. Pursuant to the Agreement...
Bracco announced a new long-term agreement that would deliver a Bracco-branded cutting-edge MR injector to the United States under an exclusive private label agreement. The two companies also announced the submission of a 510(k) premarket...
Strides Pharma Science's step-down fully owned subsidiary, Strides Pharma Global Pte. Singapore, has acquired FDA clearance for sodium sulphate, potassium sulphate, and magnesium sulphate oral solution 17.5g/ 3.13g/ 1.6g per 6 ounces (product)...
As per joint EY Parthenon-Organisation of Pharmaceutical Producers of India (OPPI) report, the Indian pharmaceutical industry can grow to $450 billion by 2047 as a result of transformative innovation, fortification of manufacturing and quality...
Sanjivani Paranteral Limited, a prominent pharmaceutical firm specializing in the production and sale of high-quality parenteral and oral solid products, has entered into a substantial deal with Hindustan Antibiotics Limited for the production of...
Simcere Pharmaceutical Group Limited signed into an exclusive licensing and partnership agreement with Connect Biopharma HongKong Limited In respect to Rademikibart, a novel IL-4R monoclonal antibody. Pursuant to the Agreement, Simcere obtains...
SK Bioscience, an innovative vaccine and biotech company dedicated to promoting human health from prevention to cure, has announced a development licensing agreement with Hilleman Laboratories, a vaccines and biologics research and development...
Senhwa Biosciences, Inc., a drug development company focused on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, announced that the US Food and Drug Administration has approved Silmitasertib (CX-4945)'s phase II...
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")